---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076522"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:29:35.677852+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M

## Summary
- Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.
- Revuforj net revenue $44.2M in Q4 (+38% vs Q3) and $124.8M in FY2025; ~1,150 prescriptions in Q4.
- Niktimvo net revenue $56M in Q4 (+22% vs Q3) and $151.6M in FY2025; Syndax collaboration revenue $42.4M FY.
- Net loss $68M (0.78/share) in Q4 and $285.4M ($3.29/share) for FY2025; cash $394.1M at year-end.
- FY2026 opex guidance ~$400M ex-stock comp; expects profitability from cash, revenue, and interest income.

## SEC filing metadata
- accession: 0001193125-26-076522
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/0001193125-26-076522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076522
- JSON: https://secwatch.observer/filing/0001193125-26-076522.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.